UNSPSC 51362005: Flurazepam dihydrochloride

This classification denotes a benzodiazepine with the molecular formula C21H23ClFN3O.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 756RDM536M, chemically known as 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1h-1,4-benzodiazepin-2(3h)-one but more generally known as flurazepam dihydrochloride, which bears US NIH Compound Identifier 3393. European Medicines Agency schedules Flurazepam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02238MIG.

Most nations, for tariff and trade purposes, schedule flurazepam dihydrochloride under HS 29339190. SMILES: CCN(CC)CCN1C2CCC(CC2C(=NCC1=O)C3CCCCC3F)CL.CL.CL.

UNSPSC 51362005 Flurazepam dihydrochloride is a Commodity code that nominally covers a specific benzodiazepine pharmaceutical product, but recent state and local procurement activity under this code shows a mismatch: the single recent opportunity tagged to it solicits naloxone and drug deactivation systems rather than flurazepam. State and local governments use codes in this family to procure pharmaceuticals and medical supplies, though the actual purchasing patterns under this particular commodity number do not align with its product name.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The response deadline was July 26, 2023, with bids submitted electronically through the county's e-Procurement Portal; vendors were required to include all shipping and delivery costs in their proposals, maintain workers' compensation and commercial general liability insurance, and comply with drug-free workplace certification and E-Verify requirements. The contract carried an initial two-year term with a one-year renewal option and included a three-month probationary period allowing termination at will. Potential FEMA funding introduced additional federal compliance obligations under the Clean Air Act and Federal Water Pollution Control Act. The source records no other recent state and local opportunities under this code, indicating either minimal current activity or systematic miscoding of pharmaceutical procurements at the commodity level.